Navigation Links
Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
Date:5/18/2009

elopment for multiple tumor types. The Company also actively engages in business development activities that include seeking strategic relationships for its product candidates and for the Company, as well as evaluating compounds and companies for in-licensing or acquisition. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for KRX-0401, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete clinical trials for KRX-0401; our ability to meet anticipated development timelines for KRX-0401 due to recruitment, clinical trial results, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website and in the American Society of Clinical Oncology's website is not incorporated by reference into this press release and is included as an inactive textual reference only.

    KERYX CONTACT: Lauren Fischer Director
                       Investor Relations
                       Keryx Biopharmaceuticals, Inc.
                       Tel: 212.531.5965
      
'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
2. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
3. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
4. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
6. Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification
7. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
8. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
10. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
11. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015  US-Australian drug discovery company, ... today confirmed its comprehensive scientific review has identified ... in areas of unmet patient need. Novogen is ... preclinical projects prior to entering into Phase 1 ... Acting Chief Executive Officer, Iain Ross ...
(Date:8/31/2015)... , Aug. 31, 2015 FLX Bio, ... development of novel cancer immunotherapies, announced today that it ... Chief Executive Officer and William Ho , M.D., ... join an experienced management team led by veterans of ... , Ph.D., Chief Scientific Officer; Jay Powers , ...
(Date:8/31/2015)... 2015 Trimb Healthcare AB ("Trimb") today announced ... Group BV ("YouMedical"), a Dutch OTC company with operations ... of approximately EUR 16 million, with solid growth and ... ambition is to build a leading international OTC company, ... goal. YouMedical gives us a stronger North European OTC ...
(Date:8/31/2015)... FL (PRWEB) , ... August 31, 2015 , ... ... bring together the world's most successful food and beverage processors, equipment manufacturers and ... competencies in product inspection and industrial weighing and formulation for manufacturers of bakery ...
Breaking Biology Technology:Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4METTLER TOLEDO Hosts Food Safety Educational Center at 2015 PROCESS EXPO 2
(Date:8/31/2015)... DUBLIN , Aug. 31, 2015 Research ... of the "Saudi Arabia Biomedical Sensors Market - ... offering. The Saudi Arabia Biomedical Sensors ... a CAGR of 3.64% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
(Date:8/26/2015)... 26, 2015 The report "Multi-Factor Authentication ... Factor), Application (Travel & Immigration, Government, Banking, Defense, Commercial ... to 2020", published by MarketsandMarkets, Multi-Factor Authentication Market is ... at a CAGR of 17.7% between 2015 and 2020. ... igures spread through 169 P ...
(Date:8/24/2015)... The consulting company Frost & Sullivan ... DERMALOG and its customized solutions and products for ... the Year Award". DERMALOG is particularly successful with a large ... -Cross reference: Picture is available at AP Images ( ... Thursday evening, in South Africa,s economic ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3
... Association (ISWA) calls the attention of the delegates of ... waste sector to reduce substantial CO 2 -emissions. ... (December 2009, www.iswa.org ) ISWA confirms that significant ... better management of solid wastes (i.e., residential and commercial ...
... TORONTO, Dec. 7 IgeaCare Solutions Inc. is pleased to ... company previously operating as IgeaCare Systems Inc. The newly formed ... funding. , IgeaCare Solutions Inc. has appointed Mr. Michael Rochon ... the new company will focus on providing a superior servicing ...
... have found that a gene already implicated in the ... the risk of being overweight during childhood. The finding ... may present an avenue for developing drugs to counteract ... childhood and adolescence. Researchers from The Children,s Hospital ...
Cached Biology News:ISWA calls attention to important contribution of waste sector to reduce substantial CO2 emissions 2IgeaCare Solutions Inc. Emerges Under New Leadership and Funding 2Type 2 diabetes gene predisposes children to obesity 2
Convenient 10X buffer concentrate used to maximize binding to the solid phase in microwell ELISA. Formulated to provide optimal pH and ionic strength for binding of antibodies and some antigens. Co...
... ester can be used to ... The covalently bound acridinium NHS ... the presence of hydrogen peroxide. ... be used as a detection ...
A trigger solution for Flashlight labeled materials....
... shift assay (EMSA) is a powerful tool ... as gel shift or gel retardation, the ... when subjected to electrophoresis, free DNA will ... Pierce LightShift Chemiluminescent EMSA Kit is a ...
Biology Products: